Locust Walk

Locust Walk operates as a global investment bank specializing in the life sciences sector. The firm provides integrated corporate development strategy and execution alongside capital raising services, partnering with companies to navigate complex strategic transactions and facilitate the creation of new ventures. Its core offerings focus on maximizing value for biotech and pharmaceutical clients through comprehensive advisory and deal-making expertise.

Geoff Meyerson co-founded Locust Walk in the fall of 2008, establishing the firm with an insight into the unmet needs of life sciences companies requiring sophisticated strategic and financial guidance. Leveraging extensive experience in building, investing in, and advising within the biotech industry, Meyerson aimed to create a platform that could effectively support businesses through critical growth and transaction phases.

The firm primarily serves founders, executives, and investors across the life sciences landscape, providing strategic and transactional support. Locust Walk’s vision centers on delivering impactful outcomes for its clients by combining deep scientific understanding with financial advisory prowess, ultimately striving to accelerate the development and commercialization of innovative healthcare solutions.

High-Level Overview

Locust Walk is a global investment bank specializing in life sciences, integrating corporate development strategy, execution, and capital raising for innovative biotech and medtech companies across all stages.[1][2][3] Its mission revolves around partnering with founders, executives, and boards to translate scientific data into actionable transactions, while Locust Walk Capital—the firm's investment arm—focuses on founder-friendly, capital-efficient creation of new biotech companies where it acts as a co-founder.[1][2] Key sectors include biopharmaceuticals and medical technology, with a track record of supporting over 300 clients through 400+ projects, generating more than $10B in deal value via buy-side/sell-side transactions and financings.[4] In the startup ecosystem, Locust Walk influences growth by providing market intelligence, strategic dealmaking, and active portfolio management, including board seats through Series A and beyond, fostering 6-10 high-conviction investments in novel platforms and de-risked clinical assets.[2]

Origin Story

Locust Walk operates as a transaction advisory firm with a base in Boston, Massachusetts, though specific founding year and key partners are not detailed in available sources.[3] It has evolved from a core focus on business transactions for emerging and established life sciences companies into a full-service global investment bank, expanding to include Locust Walk Capital as its dedicated investment vehicle.[1][2][3] The firm's growth emphasizes a global advisory network, with capabilities in Asian markets, capital raising, and multitrack deal processes, as evidenced by insights dating back to 2016 on trends like biotech financing from idea to IPO.[6] Pivotal to its trajectory is a team-based culture supporting medical innovation, highlighted by over $10B in cumulative deal value.[4]

Core Differentiators

• Integrated Model: Combines corporate development, capital raising, and investment in co-founded biotechs, ensuring alignment from strategy to execution.[1][2]
• Founder-Friendly Approach: Capital-efficient investments only in companies where Locust Walk co-founds, with board seats, global tech sourcing, and support through Series A+.[2]
• Network and Intelligence: Deep interfaces with investors, pharma, biotechs, and academics for market insights; global reach with US-based CEOs.[1][2]
• Track Record and Support: $10B+ deal value from 400+ projects; operating support via strategic dealmaking, non-dilutive partnerships, and quarterly trend reports.[2][4][6]
• Core Values: Commitment to client success, transparent communication, growth mindset, entrepreneurial spirit, and long-term relationships.[4]

Role in the Broader Tech Landscape

Locust Walk rides the wave of life sciences innovation, particularly in biotech where scientific breakthroughs demand sophisticated financing and partnering amid volatile markets.[1][6] Its timing aligns with ongoing needs for capital-efficient models in a high-burn environment, leveraging multitrack processes and non-dilutive deals to de-risk assets and accelerate from idea to IPO.[2][6] Market forces like global biotech sourcing and big pharma's appetite for clinical-stage opportunities favor its dual investment strategy in white-space platforms and commercial-potential assets.[2] The firm shapes the ecosystem by enabling efficient company creation, influencing startup trajectories through advisory scale and active involvement, as seen in its role bridging academia, biotechs, and investors.[1][4]

Quick Take & Future Outlook

Locust Walk Capital plans to launch two new co-founded biotechs annually, expanding its 6-10 company portfolio with global sourcing and extended support.[2] Trends like AI-driven drug discovery, cross-border partnerships, and activist investing in biotech will likely amplify its deal flow and influence.[6] As life sciences funding evolves toward efficiency post-2025 market cycles, Locust Walk's integrated advisory-investment model positions it to deepen impact, potentially scaling deal value beyond $10B while humanizing innovation through founder partnerships—reinforcing its role as a pivotal enabler in the global biotech arena.[1][2][4]